CNBS icon

Amplify Seymour Cannabis ETF

Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 0%
Negative

Positive
Zacks Investment Research
22 days ago
US Reclassifies Weed: Can Cannabis ETFs Give Your Portfolio a New High?
Medical marijuana's US reclassification revives cannabis ETFs like WEED, with tax relief and reform hopes fueling sharp gains across the sector.
US Reclassifies Weed: Can Cannabis ETFs Give Your Portfolio a New High?
Positive
24/7 Wall Street
1 month ago
Cannabis Rescheduling Could Unlock the Biggest MSO Rally Since 2021
Federal cannabis policy moved from theory to action this spring, and three ETFs sit closest to the trade.
Cannabis Rescheduling Could Unlock the Biggest MSO Rally Since 2021
Positive
ETF Trends
1 month ago
Cannabis ETFs: Regulatory Momentum Returns Focus
Cannabis stocks have seen renewed investor interest as federal policy momentum improves. The most important recent development was the placement of FDA-approved marijuana products and state-regulated medical marijuana products from Schedule I to Schedule III under the Controlled Substances Act.
Cannabis ETFs: Regulatory Momentum Returns Focus
Negative
24/7 Wall Street
1 month ago
The Last Cannabis ETFs Worth Your Money: Why Most Failed and 3 Are Still Trading
Cannabis ETFs entered 2026 after multiple fund closures, stalled federal reform, and a prolonged multi‑year drawdown in underlying equities.
The Last Cannabis ETFs Worth Your Money: Why Most Failed and 3 Are Still Trading
Positive
24/7 Wall Street
5 months ago
After A Surprise Win In 2025, What Will 2026 Bring For The Amplify Cannabis ETF? | CNBS
Amplify Seymour Cannabis ETF (NYSEARCA:CNBS) posted a 17% gain in 2025, but that masks the real story.
After A Surprise Win In 2025, What Will 2026 Bring For The Amplify Cannabis ETF? | CNBS
Positive
Seeking Alpha
5 months ago
CNBS: New Buy Rating On Cannabis ETF, Stoked By Positive Regulatory Trend
Amplify Seymour Cannabis ETF (CNBS) is positioned for upside as U.S. cannabis reclassification to Schedule III appears likely, marking a key industry milestone. CNBS exhibits extreme volatility, warranting only a small (1-3%) portfolio allocation; call options are not attractive due to high premiums. Current CNBS valuations—12x trailing earnings and 3x sales—are reasonable for a growth sector anticipating regulatory tailwinds.
CNBS: New Buy Rating On Cannabis ETF, Stoked By Positive Regulatory Trend
Positive
Zacks Investment Research
5 months ago
Cannabis ETF (CNBS) Hits New 52-Week High
CNBS Cannabis ETF climbs to a 52-week high, fueled by rescheduling optimism and potential further gains.
Cannabis ETF (CNBS) Hits New 52-Week High
Positive
Seeking Alpha
5 months ago
Cannabis ETFs: This Imminent Trigger Could Lead To A Definitive Repricing Of Assets
I recommend buying cannabis sector ETFs. Recent news suggests imminent U.S. regulatory easing, potentially reclassifying marijuana and unlocking significant sector value. Current MJ ETF price/sales is 1.5x; I conservatively project a move to 2.5x, implying 66% upside. Key risks include regulatory uncertainty, sector profitability challenges, and historical underperformance post-IPOs.
Cannabis ETFs: This Imminent Trigger Could Lead To A Definitive Repricing Of Assets
Positive
Zacks Investment Research
5 months ago
6 Top-Performing ETF Areas of Last Week
Cannabis, metals, space and health care led ETF gains last week. WEED, CNBS, SIL, UFO, GDXJ, PLTM and OZEM outperformed despite tech weakness.
6 Top-Performing ETF Areas of Last Week
Positive
Zacks Investment Research
5 months ago
Cannabis ETFs Soar Double-Digits on Friday: Here's Why
Cannabis ETFs explode on reform buzz. CNBS, WEED, MSOS and MJ jumped double-digits on Dec. 12, 2025 as Trump reportedly weighs reclassifying marijuana, boosting optimism.
Cannabis ETFs Soar Double-Digits on Friday: Here's Why